HomeSDZ • SWX
add
Sandoz Group AG
Previous close
CHF 38.65
Day range
CHF 38.14 - CHF 39.06
Year range
CHF 25.33 - CHF 41.16
Market cap
16.94B CHF
Avg Volume
893.51K
P/E ratio
-
Dividend yield
1.17%
Primary exchange
SWX
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 2.53B | 2.68% |
Operating expense | 1.02B | 7.11% |
Net income | 75.00M | -36.17% |
Net profit margin | 2.96 | -37.95% |
Earnings per share | — | — |
EBITDA | 270.50M | -21.93% |
Effective tax rate | 25.98% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 701.00M | 451.97% |
Total assets | 19.32B | 4.77% |
Total liabilities | 10.95B | 9.80% |
Total equity | 8.37B | — |
Shares outstanding | 430.20M | — |
Price to book | 1.99 | — |
Return on assets | 2.15% | — |
Return on capital | 3.24% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | 75.00M | -36.17% |
Cash from operations | 114.50M | 169.41% |
Cash from investing | -197.00M | -110.70% |
Cash from financing | -114.00M | -240.74% |
Net change in cash | -204.00M | -869.81% |
Free cash flow | 102.88M | -35.27% |
About
Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz. Before this, the company existed as an independent pharmaceutical manufacturer until 1996, when it was merged with Ciba-Geigy to form Novartis. Prior to the merger, it specialized in medicines used in organ transplants, such as Sandimmune, and various antipsychotics and migraine medicines. Its headquarters were in Holzkirchen, Germany and after the spin-off from Novartis, the headquarters moved to Basel, Switzerland. Sandoz is one of the leading global generics businesses. Wikipedia
Founded
1886
Website
Employees
22,633
